Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 40 studies | 39% ± 14% | |
astrocyte | 20 studies | 41% ± 21% | |
capillary endothelial cell | 13 studies | 28% ± 8% | |
macrophage | 12 studies | 29% ± 12% | |
vein endothelial cell | 12 studies | 35% ± 20% | |
fibroblast | 11 studies | 26% ± 11% | |
endothelial cell of artery | 10 studies | 26% ± 6% | |
oligodendrocyte | 10 studies | 30% ± 11% | |
endothelial cell of lymphatic vessel | 9 studies | 31% ± 14% | |
oligodendrocyte precursor cell | 9 studies | 31% ± 14% | |
adipocyte | 9 studies | 31% ± 8% | |
endothelial cell of vascular tree | 9 studies | 36% ± 21% | |
GABAergic neuron | 8 studies | 42% ± 21% | |
microglial cell | 8 studies | 26% ± 9% | |
epithelial cell | 8 studies | 39% ± 21% | |
type I pneumocyte | 7 studies | 25% ± 10% | |
mast cell | 7 studies | 23% ± 7% | |
smooth muscle cell | 7 studies | 24% ± 6% | |
pericyte | 7 studies | 26% ± 11% | |
glutamatergic neuron | 6 studies | 48% ± 25% | |
interneuron | 6 studies | 43% ± 25% | |
retinal ganglion cell | 6 studies | 29% ± 13% | |
myeloid cell | 6 studies | 22% ± 6% | |
Mueller cell | 6 studies | 41% ± 15% | |
type II pneumocyte | 6 studies | 29% ± 9% | |
dendritic cell | 5 studies | 24% ± 6% | |
retinal cone cell | 5 studies | 22% ± 7% | |
club cell | 5 studies | 26% ± 10% | |
natural killer cell | 4 studies | 22% ± 4% | |
glomerular endothelial cell | 4 studies | 52% ± 6% | |
retinal pigment epithelial cell | 4 studies | 40% ± 21% | |
cardiac muscle cell | 4 studies | 20% ± 1% | |
lymphocyte | 4 studies | 23% ± 7% | |
amacrine cell | 4 studies | 26% ± 11% | |
retina horizontal cell | 4 studies | 22% ± 7% | |
retinal rod cell | 4 studies | 20% ± 3% | |
monocyte | 4 studies | 25% ± 4% | |
basal cell | 4 studies | 30% ± 24% | |
neuron | 4 studies | 44% ± 17% | |
endothelial cell of sinusoid | 3 studies | 35% ± 14% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 19% ± 3% | |
GABAergic interneuron | 3 studies | 23% ± 3% | |
glial cell | 3 studies | 20% ± 4% | |
granule cell | 3 studies | 21% ± 7% | |
progenitor cell | 3 studies | 24% ± 2% | |
plasma cell | 3 studies | 25% ± 5% | |
endocardial cell | 3 studies | 41% ± 18% | |
mesothelial cell | 3 studies | 27% ± 9% | |
mononuclear phagocyte | 3 studies | 21% ± 4% | |
ciliated cell | 3 studies | 31% ± 10% | |
retinal bipolar neuron | 3 studies | 20% ± 3% | |
ON-bipolar cell | 3 studies | 23% ± 7% | |
glycinergic amacrine cell | 3 studies | 27% ± 7% | |
rod bipolar cell | 3 studies | 30% ± 10% | |
hepatocyte | 3 studies | 39% ± 23% | |
abnormal cell | 3 studies | 31% ± 18% | |
connective tissue cell | 3 studies | 22% ± 3% | |
ependymal cell | 3 studies | 47% ± 18% | |
T cell | 3 studies | 19% ± 1% | |
alveolar macrophage | 3 studies | 25% ± 7% | |
goblet cell | 3 studies | 42% ± 29% | |
transit amplifying cell | 3 studies | 37% ± 28% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4452.47 | 1443 / 1445 | 100% | 36.90 | 183 / 183 |
lung | 100% | 6856.23 | 578 / 578 | 100% | 23.52 | 1153 / 1155 |
ovary | 100% | 4621.65 | 180 / 180 | 99% | 18.56 | 427 / 430 |
brain | 100% | 4179.06 | 2637 / 2642 | 99% | 31.83 | 701 / 705 |
prostate | 100% | 4709.02 | 245 / 245 | 98% | 28.56 | 494 / 502 |
breast | 100% | 6347.78 | 459 / 459 | 98% | 31.41 | 1100 / 1118 |
thymus | 100% | 6984.67 | 653 / 653 | 98% | 27.23 | 590 / 605 |
stomach | 100% | 3804.39 | 359 / 359 | 97% | 28.69 | 277 / 286 |
kidney | 100% | 4083.49 | 89 / 89 | 96% | 27.41 | 866 / 901 |
intestine | 100% | 4310.14 | 966 / 966 | 95% | 21.54 | 503 / 527 |
pancreas | 99% | 2307.25 | 325 / 328 | 96% | 18.60 | 171 / 178 |
uterus | 100% | 6365.20 | 170 / 170 | 94% | 14.62 | 430 / 459 |
bladder | 100% | 4533.57 | 21 / 21 | 93% | 15.49 | 471 / 504 |
adrenal gland | 100% | 4661.29 | 258 / 258 | 90% | 12.73 | 208 / 230 |
skin | 100% | 4376.73 | 1807 / 1809 | 88% | 21.02 | 416 / 472 |
liver | 100% | 1901.03 | 225 / 226 | 80% | 9.70 | 324 / 406 |
adipose | 100% | 6687.84 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6270.09 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 3529.77 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 98% | 2891.06 | 845 / 861 | 0% | 0 | 0 / 0 |
muscle | 92% | 1415.36 | 735 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 15.21 | 39 / 45 |
eye | 0% | 0 | 0 / 0 | 78% | 22.40 | 62 / 80 |
lymph node | 0% | 0 | 0 / 0 | 59% | 6.94 | 17 / 29 |
peripheral blood | 38% | 1153.64 | 357 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006897 | Biological process | endocytosis |
GO_0061024 | Biological process | membrane organization |
GO_0014829 | Biological process | vascular associated smooth muscle contraction |
GO_0048015 | Biological process | phosphatidylinositol-mediated signaling |
GO_0090050 | Biological process | positive regulation of cell migration involved in sprouting angiogenesis |
GO_0048008 | Biological process | platelet-derived growth factor receptor signaling pathway |
GO_0036092 | Biological process | phosphatidylinositol-3-phosphate biosynthetic process |
GO_0048268 | Biological process | clathrin coat assembly |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0006887 | Biological process | exocytosis |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0007173 | Biological process | epidermal growth factor receptor signaling pathway |
GO_0016477 | Biological process | cell migration |
GO_0006661 | Biological process | phosphatidylinositol biosynthetic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005942 | Cellular component | phosphatidylinositol 3-kinase complex |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0030136 | Cellular component | clathrin-coated vesicle |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0031982 | Cellular component | vesicle |
GO_0046934 | Molecular function | 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity |
GO_0035091 | Molecular function | phosphatidylinositol binding |
GO_0005524 | Molecular function | ATP binding |
GO_0016303 | Molecular function | 1-phosphatidylinositol-3-kinase activity |
GO_0030276 | Molecular function | clathrin binding |
GO_0035005 | Molecular function | 1-phosphatidylinositol-4-phosphate 3-kinase activity |
Gene name | PIK3C2A |
Protein name | Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PI3K-C2-alpha) (PtdIns-3-kinase C2 subunit alpha) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphoinositide 3-kinase-C2-alpha) Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha |
Synonyms | |
Description | FUNCTION: Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin-mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin-independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. Involved in the regulation of ciliogenesis and trafficking of ciliary components . . |
Accessions | E9PPP3 ENST00000532035.1 ENST00000533645.1 L7RRS0 O00443 ENST00000691414.1 [O00443-1] A0A0C4DGF9 ENST00000265970.11 [O00443-1] |